Recent Quotes (30 days)

You have no recent quotes
chg | %

GlaxoSmithKline plc news

   Watch this stock
Showing stories 1 - 10 of about 66   

Articles published

GSK 1,485.22 -3.28 (-0.22%)
price chart
Bonds Resurrected as Glaxo Leads Rising Sales
GlaxoSmithKline Plc (GSK)'s $5 billion offering, its first dollar-denominated sale in more than four years, led issuance of at least $55.1 billion this week following $45.8 billion in the period ended April 27, according to data compiled by Bloomberg.
Related articles »  
GSK partner Pronova wins fish oil drug patent fight
LONDON (Reuters) - Norway's Pronova BioPharma PRON.OL, which supplies the omega-3 heart medicine Lovaza to GlaxoSmithKline (GSK.L), has defeated a U.S. patent challenge from two generics companies, sending Pronova shares 28 percent higher ...
GSK partner Pronova wins Lovaza patent case against Teva & Par Pharma
Pronova Defeats Teva, Par In Lovaza Patent Suit  Law360 (subscription)
Related articles »  
GlaxoSmithKline: Complied With Indian Rules for Drug Approval
BANGALORE - GlaxoSmithKline PLC said Thursday it was granted a waiver on conducting clinical trials in India for ambrisentan, its drug to treat pulmonary arterial hypertension, as local rules allow such a concession for drugs treating a "rare disease ...
Probe Reveals Major Flaws in Drug Approval  Wall Street Journal (blog)
Indian Drug Regulator Accused of Corruption and Collusion  Bloomberg
Related articles »  
Glaxo's Melanoma Cocktail Slows Cancer in Study
GlaxoSmithKline Plc (GSK)'s combination of two experimental melanoma medicines slowed the progress of cancer with few skin complications in an early study, suggesting the combo may not have as many side effects as existing single-drug treatments.
Dabrafenib And Trametinib: Melanoma Drug Combo Shows Promise In Small Trial  Huffington Post
Related articles »  
Glaxo to Begin Hostile Offer for Human Genome Sciences
Glaxo's bid is part of a wave of takeover activity in the pharmaceutical industry as drugmakers seek new products. Roche Holding AG (ROG) made a hostile offer for Illumina Inc. in January, and abandoned it last month.
Glaxo makes $2.6bn hostile bid for Human Genome
Related articles »  
Germany joins UK in spurning GSK's new lupus drug
The drug, which was discovered by Human Genome and developed with GSK to combat a disease that causes the immune system to attack joints and organs, is at the centre of a $2.6 billion takeover bid by GSK for its U.S. biotech partner. GSK, Britain's ...
Related articles »  
GlaxoSmithKline Launches Hostile Takeover Bid for Human Genome Sciences
GlaxoSmithKline Plc (NYSE: GSK), Britain's biggest drugmaker, will mount a $2.6 billion hostile takeover bid for Human Genome Sciences Inc. (NASDAQ: HGSI), the company announced Wednesday.
Related articles »  
Glaxo Diabetes Drug Data Revealed Amid Hostile Takeover
GlaxoSmithKline Plc (GSK) will reveal detailed results today on an experimental treatment for diabetes that's part of the reason for a $2.6 billion hostile takeover bid for Human Genome Sciences Inc. (HGSI:US), its partner on the drug.
Related articles »  
Glaxo Scientist, Surgeon Targeting Historic British Hockey Gold
MacLeod, 27, also worked for GlaxoSmithKline Plc (GSK), the U.K.'s biggest drugmaker, as a sports scientist on its Lucozade energy drink.
Related articles »  
Human Genome in Talks With Potential Suitors
Human Genome Sciences Inc. said it's in talks with �major� pharmaceutical and biotechnology companies about a potential transaction and adopted measures to avoid a hostile takeover by GlaxoSmithKline Plc. (GSK). Human Genome entered into ...
Human Genome digs in against Glaxo  The Deal Pipeline
Related articles »